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ABSTRACT
Introduction Ischaemic stroke is the most prevalent 
type of stroke and is characterised by a myriad of 
pathological events triggered by a vascular arterial 
occlusion. Disruption of the blood- brain barrier (BBB) is a 
key pathological event that may lead to fatal outcomes. 
However, it seems to follow a multiphasic pattern that 
has been associated with distinct biological substrates 
and possibly contrasting outcomes. Addressing the 
BBB permeability (BBBP) along the different phases 
of stroke through imaging techniques could lead to a 
better understanding of the disease, improved patient 
selection for specific treatments and development of 
new therapeutic modalities and delivery methods. This 
systematic review will aim to comprehensively summarise 
the existing evidence regarding the evolution of the BBBP 
values during the different phases of an acute ischaemic 
stroke and correlate this event with the clinical outcome of 
the patient.
Methods and analysis We will conduct a computerised 
search on Medline, EMBASE, Cochrane Central Register of 
Controlled Trials, Scopus and Web of Science. In addition, 
grey literature and  ClinicalTrials. gov will be scanned. We 
will include randomised controlled trials, cohort, cross- 
sectional and case- controlled studies on humans that 
quantitatively assess the BBBP in stroke. Retrieved studies 
will be independently reviewed by two authors and any 
discrepancies will be resolved by consensus or with a third 
reviewer. Reviewers will extract the data and assess the 
risk of bias of the selected studies. If possible, data will 
be combined in a quantitative meta- analysis following the 
guidelines provided by Cochrane Handbook for Systematic 
Reviews of Interventions. We will assess cumulative 
evidence using the Grading of Recommendations, 
Assessment, Development and Evaluation approach.
Ethics and dissemination Ethical approval is not 
needed. All data used for this work are publicly available. 
The result obtained from this work will be published in 
a peer- reviewed journal and disseminated in relevant 
conferences.
PROSPERO registration number CRD42019147314.
INTRODUCTION
Stroke is the second leading cause of 
mortality and morbidity worldwide.1–4 Every 
year around 14 million people suffer a 
stroke, 5.5 million of which die1 and another 
5 million stay permanently disabled, repre-
senting a significant concern for public 
health and society.2 Acute ischaemic stroke 
(AIS) accounts for approximately 85% of all 
strokes,1 3 4 it restricts blood flow to a specific 
region of the brain leading to death of the 
compromised tissue.5 6 Currently, the only 
available and effective treatment to limit this 
situation is recanalisation therapy, to restore 
the normal blood flow,7 but these therapies 
can only be given to less than 5% of patients 
due to their narrow therapeutic window.4 7 
Treating patients outside this window could 
contribute to additional tissue damage and 
increase in the risk of haemorrhagic transfor-
mation (HT).7 8
The blood- brain barrier (BBB) is a dynamic 
physiological structure that constitutes an 
interface between the vasculature system and 
the neural tissues. It regulates the transport of 
Strengths and limitations of this study
 ► To our knowledge this is the first systematic review 
that will focus on the progression of the blood- brain 
barrier permeability (BBBP) during acute ischaemic 
stroke (AIS) and its clinical consequences.
 ► This protocol has been developed following 
Preferred Reporting Items for Systematic Review 
and Meta- Analysis Protocols.
 ► This systematic review could help to guide con-
ventional recanalisation treatments outside the 
therapeutic windows and other innovative delivery 
treatments in later stage of AIS.
 ► We will include all types of studies, not imposing any 
restriction on language or year.
 ► The vast heterogeneity that can arise from the use 
of different BBBP imaging techniques, the pharma-
cokinetic models used and the different permeability 
parameters yield from each technique, may prevent 
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substances in a bidirectional way9 and protects the central 
nervous system from unwanted compounds, playing a 
crucial role in maintaining its homeostasis.9 10 During the 
process of ischaemia the BBB undergoes a dysfunction9 11 
that leads to an increase of its permeability,10 enabling 
the passage of large molecules, fluids and blood into the 
brain interstitium.8 9 This pathological leakage is associ-
ated with a worst outcome after AIS3 8 12 and is known to 
persist for several days7 following a time- course mediated 
by complex pathophysiological events with different clin-
ical implications.13–15 During the first hours after stroke, 
namely the hyperacute and acute phases, the insult trig-
gers ischaemic cell death which leads to a higher risk of 
HT.16 17 In a late acute/early subacute stage, the BBB is 
disrupted due to the secondary ischaemic injury which 
causes inflammatory cell infiltration and tissue scarring 
and a further BBB permeability (BBBP) increase.17 18 In 
a later subacute stage, the BBBP relies on physiological 
recovery processes such as neoangiogenesis, as demon-
strated in both animals19 20 and humans.21 Whereas the 
existence of this permeability process is unequivocal, its 
concrete evolution is not yet certain.
Several longitudinal animal studies have tried to explain 
this event. Some studies point to an ‘open- close- open’ 
biphasic pattern in which the BBB has increased permea-
bility at a first stage followed by a return to normal values 
and a second permeability increase.22–24 Nonetheless 
these studies show differences on the open/close times 
and more recent literature points to a more continuous 
opening of the BBB with biphasic permeability peaks 
but without total closing.25–28 A first BBBP increase has 
been shown to appear as soon as 3–6 hours after occlu-
sion, followed by a decrease but not a total recovery, and 
a second peak at the early subacute stage.26 27 29 Studies 
extending the BBBP quantification time- points have 
reported a further increased permeability up to 1,27 29 273 
and even 5 weeks28 30 after occlusion, suggesting that the 
BBB could remain open until months after the onset of 
stroke.
Very few human studies have focused on studying this 
evolution11 21 31 32 and even though these studies point to a 
continuous opening of the BBB, they do not offer a clear 
and collective evidence on the magnitude of this opening 
in the different phases. A quantitative assessment of the 
BBB disruption through its permeability could add valu-
able information in the evaluation of patients with AIS.
Three main imaging techniques are used to evaluate 
BBBP: CT, MRI and positron emission tomography 
(PET).33 Nonetheless, due to the limited availability 
of PET, the ‘permeability imaging’ term is used mainly 
for MRI and CT.7 These specific imaging tools are 
able to measure the BBBP in vivo in a non- invasive 
manner.3 9 11 34–37 In short, these imaging modalities 
quantify the rate and amount at which a specific contrast 
agent leaves the blood stream and enters the brain paren-
chyma12 34 38 using mathematical models able to describe 
the physiological characteristics of the BBB such as vessel 
permeability, vessel surface area product and tissue 
volume fraction.11 39 40 In clinical practice this informa-
tion has been used as a diagnostic tool for differential 
diagnosis, and also to support decisions for safer and 
improved recanalisation therapies for patients who had a 
stroke in an extended time window.7–9 11 38 41–43
Nonetheless, although there are important systematic 
reviews that focus on the implications of imaging and 
increased permeability on stroke outcome,44 45 and on 
the utility of perfusion imaging in determining treat-
ment eligibility in patients who had an acute stroke,46 to 
date there are no systematic reviews, to our knowledge, 
focusing on the development of the BBBP during the 
phases of AIS.
Ideally, this knowledge would help not only in 
extending the treatment window, but also in the develop-
ment of future treatment options such as delivery system 
strategies for neuroprotective or neurorestorative treat-
ments that aim to use the BBB as a therapeutic vehicle 
or target. Therefore, there is a need to perform a system-
atic review and meta- analysis on the BBBP dynamics after 
AIS to gather larger sample sizes of patients and create 
a concrete understanding of the subject. This system-
atic review will provide an insight on the evolution of 
the permeability of the BBB in patients affected by AIS 
through the different stages of the stroke and its rele-
vance in the patient outcome and treatment.
Objective
The main objective of this work is to carry out a system-
atic review and meta- analysis on the BBBP during the 
different phases of an acute ischaemic stroke with the aim 




This work will identify randomised controlled trials 
(RCTs), cohort studies (prospective or retrospective), 
cross- sectional studies and case- controlled studies that 
quantify BBBP in patients suffering from AIS. Studies 
fulfilling the eligibility criteria shown in table 1 will be 
selected for further review. If more than one article reports 
the same study, the article with the largest sample size or 
reporting more relevant data for our specific aim will be 
selected. No restriction regarding publication year will be 
set; therefore, we will be including studies since incep-
tion to 31st of July 2019. In addition, no language restric-
tion will be applied. If a study in a non- understandable 
language is obtained, we will consider its suitability for 
our study by its English abstract and if the information is 
interesting enough to be included, the paper will be sent 
to a professional translator.
Information sources
We will conduct a comprehensive computerised literature 
search strategy to find the studies that will take part in 
















pen: first published as 10.1136/bm






3Bernardo- Castro S, et al. BMJ Open 2020;10:e039280. doi:10.1136/bmjopen-2020-039280
Open access
and unpublished studies in the following databases: 
PubMed/Medline, EMBASE, Web of Science, Scopus and 
Cochrane Central Register of Controlled Trials. Other 
electronic platforms such as  ClinicalTrials. gov will be 
scanned to keep up with ongoing or unpublished clin-
ical trials. If any relevant unpublished trial is found, the 
corresponding author listed will be contacted to obtain 
the required information. If no response is given or, if 
the author decides not to share the data, this will be listed 
as the reason for exclusion of said trial. In addition to 
this electronic search, a supplementary search of the grey 
literature will be conducted with the aim of including all 
possible existing articles on the subject. No pre- prints will 
be included on the study.
Search strategy
The search strategy will include the following terms 
and all of its variants in multiple combinations adapted 
to each one of the databases regarding its own special 
requirements as shown in table 2: ‘stroke’, ‘permea-
bility’, ‘blood brain barrier’, ‘imaging’, ‘neuroimaging’. 
The search of the grey literature will include a by- hand 
search of relevant articles in the listed bibliography 
of the selected studies and important reviews on the 
subject, conference papers and a Google search of the 
used terms.
Data management
All publications arising from the literature search 
conducted will be imported to the Mendeley citation soft-
ware where duplicates will be managed and erased and 
titles/abstracts of all records will be scanned.
Selection process
Two independent reviewers will conduct the selection 
process. All records identified in the search stage will be 
screened by title/abstract and studies clearly not matching 
the criteria will be discarded. The remaining studies will 
be full- text reviewed and included or discarded according 
to the inclusion/exclusion criteria. Any disagreement 
between the reviewers will be resolved by consensus or 
by a third one if necessary. Reasons for the exclusion of 
full- text records will be recorded. Details on the selection 
process of the studies will be documented into a flow 
chart following the Preferred Reporting Items for System-
atic Reviews and Meta- Analyses47 as presented in figure 1.
Data collection process
To ensure that all relevant information is captured, and to 
minimise the risk of bias, two reviewers will independently 
extract the information from the studies following the 
same pilot form. Any disagreement will be resolved by 
consensus. The data extracted will be reviewed and vali-
dated by a third reviewer.
Data items
Four main categories of data will be extracted from all 
studies selected: (1) features of the study; (2) patients’ 
characteristics; (3) intervention; (4) outcome. Among 
these categories a number of items will be collected as 
presented in table 3.
Since the main aim of this work is to study the BBBP 
values in the different phases of stroke, we will form the 
following groups according to time from onset to imaging 
reported in each study:
1. Hyperacute stage: 6 hours or less.
2. Acute stage: between 6 and 48 hours.
3. Subacute stage: between 3 and 9 days.
4. Chronic stage: 30 or more days.
For any study reporting more than one BBBP meas-
urement, each of the measurements will be considered 
as an independent study and will be placed in the corre-
sponding group according to the time- points established 
above. These values will be identified as author, year 
followed by the name of the corresponding stage.
Outcomes and prioritisation
This work has three primary outcomes: (1) the compar-
ison of the quantitative permeability values across time 
after stroke; (2) the association between the different 
BBBP values and the functional outcome of patients who 
had an acute stroke; (3) association between permeability 
values and the recanalisation treatment given.
When and if possible, the following secondary outcomes 
will be measured: (1) the association between the different 
BBBP values and haemorrhagic transformation; (2) 
Table 1 Inclusion/exclusion criteria for study selection
Inclusion criteria Exclusion criteria





Lacunar strokes (subcortical ischaemic 
lesion with a diameter under 15 mm in 




Mild stroke (NIHSS below 6)
Studies with a 
follow- up for 
clinical outcome
Haemorrhagic stroke
BBBP evaluation through non- imaging 
techniques
BBBP evaluation in other non- AIS 
diseases
No primary research
Reports just defining a study protocol
Case- report studies
Studies not reporting time from onset to 
imaging
Studies not reporting contralateral 
permeability values
AIS, acute ischaemic stroke; BBBP, blood- brain barrier 
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Table 2 Retrieval search strategy
PubMed
Query Search
#1 ‘Stroke’ (MeSH terms) OR ‘stroke’ OR ‘cerebral stroke’ OR ‘ischemic stroke’ OR ‘acute stroke’ OR ‘acute ischemic 
stroke’ OR ‘apoplexy’ OR ‘cerebral apoplexy’ OR ‘cerebrovascular accident’ OR ‘acute cerebrovascular accident’ OR 
‘brain vascular accident’ OR ‘CVA’
#2 ‘Blood- Brain Barrier’ (MeSH terms) OR ‘Blood- Brain Barrier’ OR ‘Blood Brain Barrier’ OR ‘Brain- Blood Barrier’ OR 
‘Hemato Encephalic Barrier’ OR ‘Hemato- Encephalic Barrier’
#3 ‘Permeability’ (MeSH terms) OR ‘Permeability’ OR ‘Leakage’
#4 ‘Diagnostic Imaging’ (MesH) OR ‘Neuroimaging’ (MeSH Terms) OR ‘Neuroimaging’ OR ‘Brain Imaging’ OR ‘Magnetic 
Resonance Imaging’ (MeSH Terms) OR ‘Magnetic Resonance Imaging’ OR ‘MRI’ OR ‘MRI scan’ OR ‘Functional 
MRI’ OR ‘fMRI’ OR ‘Computed Tomography Angiography’ (MeSH Terms) OR ‘Computed Tomography Angiography’ 
OR ‘Computed Tomography’ OR ‘CT’ OR ‘CT angiography’ OR ‘ dynamic contrast enhanced MRI’ OR ‘dynamic 
susceptibility contrast MRI’ OR ‘computed tomography perfusion’
#5 Search #1 AND #2 AND #3 AND #4
EMBASE
#1 ‘cerebrovascular accident’/exp OR ‘brain ischemia’/exp OR ‘cerebrovascular accident’ OR ‘stroke patient’ OR ‘brain 
ischemia’ OR ‘stroke’ OR ‘acute ischemic stroke’ OR ‘ischemic stroke’ OR ‘apoplexy’ OR ‘cerebral apoplexy’ OR 
‘brain apoplexy’
#2 ‘blood brain barrier’/exp OR ‘blood brain barrier’ OR ‘hemato encephalic barrier’ OR ‘hemato- encephalic barrier’
#3 ‘permeability’/exp OR ‘permeability’ OR ‘leakage’
#4 ‘diagnostic imaging’/exp OR ‘neuroimaging’/exp OR ‘functional magnetic resonance imaging/exp OR ‘nuclear 
magnetic resonance imaging/exp OR ‘nuclear magnetic resonance’/exp OR ‘computer assisted tomography’/exp 
OR ‘neuroimaging’ OR ‘nuclear magnetic resonance imaging OR ‘mri’ OR ‘functional magnetic imaging’ OR ‘fmri’ OR 
‘computer assisted tomography’ OR ‘computed tomographic angiography’ OR ‘ct’ OR ‘dynamic contrast enhanced 
MRI’ OR ‘dynamic susceptibility contrast MRI’ OR ‘computed tomography perfusion’
#5 #1 AND #2 AND #3 AND #4
Scopus
#1 TITLE- ABS- KEY (‘stroke’) OR TITLE- ABS- KEY (‘ischemic stroke’) OR TITLE- ABS- KEY (‘acute ischemic stroke’) OR 
TITLE- ABS- KEY (‘cerebral apoplexy’) OR TITLE- ABS- KEY (‘cerebrovascular accident’) OR TITLE- ABS- KEY (‘acute 
cerebrovascular accident’) OR TITLE- ABS- KEY (‘brain apoplexy’) OR TITLE- ABS- KEY (‘CVA’)
#2 (‘blood- brain barrier’) OR TITLE- ABS- KEY (‘hemato encephalic barrier’) OR TITLE- ABS- KEY (‘blood brain barrier’) OR 
TITLE- ABS- KEY (‘hemato- encephalic barrier’)
#3 TITLE- ABS- KEY (‘permeability’) OR TITLE- ABS- KEY (‘leakage’)
#4 TITLE- ABS- KEY (‘neuroimaging’) OR TITLE- ABS- KEY (‘magnetic resonance imaging’) OR TITLE- ABS- KEY (‘functional 
magnetic resonance imaging’) OR TITLE- ABS- KEY (‘MRI’) OR TITLE- ABS- KEY (‘fMRI’) OR TITLE- ABS- KEY 
(‘computed tomography’) OR TITLE- ABS- KEY (‘computed tomography angiography’) OR TITLE- ABS- KEY (‘CT’) OR 
TITLE- ABS- KEY (‘dynamic contrast enhanced MRI’) OR TITLE- ABS- KEY (‘dynamic susceptibility contrast MRI’) OR 
TITLE- ABS- KEY (‘computed tomography perfusion’)
Cochrane Central Register of Controlled Trials
#1 (‘blood brain barrier’ OR ‘hemato encephalic barrier’ OR ‘hemato- encephalic barrier’) AND (‘permeability’ OR 
‘leakage’) AND (‘cerebrovascular accident’ OR ‘stroke patient’ OR ‘brain ischemia’ OR ‘stroke’ OR ‘acute ischemic 
stroke’ OR ‘ischemic stroke’ OR ‘apoplexy’ OR ‘cerebral apoplexy’ OR ‘brain apoplexy’) AND (‘neuroimaging’ OR 
‘nuclear magnetic resonance imaging OR ‘mri’ OR ‘functional magnetic imaging’ OR ‘fmri’ OR ‘computer assisted 
tomography’ OR ‘computed tomographic angiography’ OR ‘ct’ OR ‘dynamic contrast enhanced MRI’ OR ‘dynamic 
susceptibility contrast MRI’ OR ‘computed tomography perfusion’)
Web of Science
#1 TS=(‘blood brain barrier’ OR ‘hemato encephalic barrier’ OR ‘hemato- encephalic barrier’) AND TS=(‘permeability’ OR 
‘leakage’) AND TS=(‘cerebrovascular accident’ OR ‘stroke patient’ OR ‘brain ischemia’ OR ‘stroke’ OR ‘acute ischemic 
stroke’ OR ‘ischemic stroke’ OR ‘apoplexy’ OR ‘cerebral apoplexy’ OR ‘brain apoplexy’) AND TS=(‘neuroimaging’ OR 
‘nuclear magnetic resonance imaging OR ‘mri’ OR ‘functional magnetic imaging’ OR ‘fmri’ OR ‘computer assisted 
tomography’ OR ‘computed tomographic angiography’ OR ‘ct’ OR ‘dynamic contrast enhanced MRI’ OR ‘dynamic 
susceptibility contrast MRI’ OR ‘computed tomography perfusion’)
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association between any clinical feature/stroke predictor 
(age, hypertension, diabetes) and the BBBP.
Risk of bias in individual studies
With the aim of minimising bias, the methodological 
quality of all studies included in the systematic review, will 
be assessed independently by two reviewers. Since we will 
be including diverse types of studies, we will use different 
tools to assess the risk of bias depending on the charac-
teristics of the studies, tuning these tools if necessary. For 
the RCT we will be using the Cochrane Collaboration’s 
tool for assessing risk of bias in randomised trials.48 This 
tool covers seven sources of bias: (1) random sequence 
generation; (2) allocation concealment; (3) blinding 
of participants and personnel; (4) blinding of outcome 
assessment; (5) incomplete outcome data; (6) selective 
reporting and (7) other bias. The risk of bias for each 
domain will be graded as high, low or unclear based on 
the relevant information extracted from each study. Low 
risk of bias will be given to the study if all of the domains 
are marked as low risk; intermediate risk of bias will be 
Figure 1 Flow chart diagram presenting the selection process for the studies. AIS, acute ischaemic stroke; BBBP, blood- brain 
barrier permeability; CENTRAL, Cochrane Central Register of Controlled Trials.
Table 3 Data items to be collected from the selected studies
Features of the study Patients’ characteristics Intervention Outcome
Title, author Age, gender Time from onset to imaging Permeability values
Study design Comorbidities Imaging characteristics Final lesion (volume)
Recruitment procedure and 
duration
NIHSS at admission BBBP assessment 
characteristics
Follow- up (length, number)
Number of participants Stroke aetiology (TOAST 
classification)
Reperfusion treatment given Clinical outcome (NIHSS and 
mRS)
Imaging modality Vascular territory   Haemorrhagic transformation
BBBP, blood- brain barrier permeability; mRS, Modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of ORG 
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given when at least one of the domains is graded with 
unclear risk; high risk of bias will be given if high risk is 
given to at least one of the domains of the checklist.
For non- randomised trials we will use the Newcastle- 
Ottawa Scale for assessing the quality of non- randomised 
studies in meta- analysis.49 These studies will be assessed 
based on three perspectives: (1) selection of study groups, 
(2) comparability of the groups; (3) ascertainment of 
exposure (in case–control studies) or outcome of interest 
(in cohort studies). This scale proposes a system in which 
a high- quality choice will be granted by a star. A maximum 
of 9 stars for study can be given. We will consider a score 
of 7 or more as low risk of bias/high- quality and less than 
5 will be considered as high risk of bias/poor quality.50 51
Any disagreement between the two reviewers will be 
resolved by consensus or by a third reviewer if necessary.
Data synthesis
This systematic review will include a quantitative meta- 
analysis if possible. The statistical analysis will be carried 
out taking into account the guidelines provided by 
Cochrane Handbook for Systematic Reviews of Inter-
ventions.48 As our main outcome will be presented as 
continuous data (permeability values), we will use the 
mean difference or the standardised mean difference 
and the respective 95% CI to combine the results. We will 
test the consistency and heterogeneity of the studies with 
the Higgins I2 statistic that can also be used to describe 
heterogeneity among subgroups.52 Following the direc-
tion given by Higgins et al52 we will consider ≤25% as 
low heterogeneity, between 25% and 50% as moderate 
heterogeneity and >75% as high heterogeneity. If the I2 
value is ≤50% (low to moderate heterogeneity), we will 
use the fixed effect model for data synthesis; if it is greater 
than 50%, we will use the random effects model. If the 
heterogeneity values are over 75%, we will search for the 
possible sources of this high heterogeneity, including 
reviewing the methodological processes of the selected 
studies, and search for outliers or influential cases that 
may distort the results of the analysis. Any possible outlier 
or influential case, as well as studies presenting with poor 
methodological quality and/or a high or critical risk of 
bias, will be excluded in a further sensitivity analysis.
If we are not able to collect the appropriate outcome 
information or not enough studies are retrieved for the 
different stages, we will consider that a quantitative meta- 
analysis is not feasible and we will conduct a narrative 
description.53
Subgroup analysis
When possible, the following subgroups will be made:
 ► Subgroups according to the imaging technique used 
with the aim of reducing possible heterogeneity 
arising from this methodological variety.
 ► Subgroups according to the treatment received.
 ► Subgroups according to the presence/absence of HT.
 ► Subgroups according to the mRS 90 days value: (1) 
mRS 0–1; (2) mRS 2–5
We will compare the permeability values among the 
subgroups and, if possible, correlate these with the 
different features/predictors of stroke.
Meta-bias(es)
To assess publication bias, we will conduct a funnel plot 
following the recommendation of the Cochrane Hand-
book for Systematic Reviews of Interventions48 and a 
complemental Egger’s test in order to quantify the funnel 
plot’s asymmetry.
Confidence in cumulative evidence
The strength of the body evidence will be assessed using 
the Grading Recommendations Assessment, Develop-
ment and Evaluation.48
Patient and public involvement
This is a protocol for a systematic review that will be based 
on previously published data, therefore no participant 
recruitment will take place. The involvement of partici-
pants on the recruitment and dissemination of results is 
not applicable.
ETHICS AND DISSEMINATION
This work will be based in data that are public and already 
published, therefore an ethical approval would not be 
necessary. The result obtained from this work will be 
published in a peer- reviewed journal and disseminated in 
relevant conferences. If any amendments are needed due 
to deviations from this protocol in the execution of the 
study, these amendments will be recorded and noted in 
the publication.
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